GSK

GSK news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

SEC Filings

GSK-Licensed Bone Cancer Drug Cuts Risk Of Progression Or Death 67% In China Trial

Patients on Ris-Rez stayed progression-free a median 5.5 months versus 1.4 months on chemotherapy in relapsed osteosarcoma.

SEC Filings

FDA Approves GSK's Jemperli For MSI-H Rectal Cancer On 68% Response Rate In Single-Arm Trial

The accelerated approval came ahead of the FDA's target date, but the independent-review result behind the trial's main goal is 47% and still maturing.